Arcutis Biotherapeutics

Discovering and developing innovative topical medicines for the treatment of skin diseases

Arcutis is a Frazier-founded company developing potentially best-in-class topical medicines for the treatment of skin diseases. The company’s lead program, ARQ-151, is a topical formulation of roflumilast that is currently in Phase 2 studies for the treatment of plaque psoriasis and atopic dermatitis. The company’s second program, ARQ-250, is a topical JAK1-inhibitor in preclinical development for the treatment of various autoimmune diseases affecting the skin. Arcutis co-founder and Frazier Operating Partner Bhaskar Chaudhuri serves as Executive Chairman of the Board of Directors.

Year of Investment
Life Sciences
Westlake Village, California